Delta Air Lines has announced a new global funding approach for breast cancer research, committing over $36m to the cause. This move marks 21 years of partnership with the Breast Cancer Research Foundation (BCRF). The airline's collaboration with BCRF has funded over 720,000 hours of breast cancer research since 2005. This research has contributed significantly to improving understanding, diagnosis, and treatment of the disease.
As part of its latest initiative, Delta is establishing The Delta Air Lines Fund in Support of Global Breast Cancer Research. This fund will consolidate donations made through its Team Delta donation platform under a single fund. The new structure aims to create more opportunities for scientists worldwide to secure research funding, encouraging international collaboration and data-driven discoveries.
According to Kristen Manion Taylor, Delta's Senior Vice President of Brand Experience, breast cancer is personal to many people. The airline's partnership with BCRF has helped make a significant difference in the lives of those affected. The expansion of this partnership comes at a critical time, with breast cancer continuing to affect a large number of people in the United States. BCRF estimates that 324,580 people will be diagnosed with breast cancer in the US in 2026.
The OPTIMA trial is an example of research that has advanced personalized approaches to breast cancer treatment. The trial examined whether some patients with high-risk breast cancer could safely avoid chemotherapy. This research was made possible through funding from BCRF and has helped doctors make more informed treatment decisions. Such research demonstrates the impact of sustained funding on translating scientific discoveries into personalized treatment options.
Donna McKay, President and Chief Executive Officer of BCRF, emphasizes the importance of continued investment in research to improve outcomes for people living with breast cancer. The new fund established by Delta will help create new opportunities for researchers worldwide. McKay expressed excitement about building on the momentum of their partnership with Delta to make progress towards a future where more people can live longer, healthier lives after a breast cancer diagnosis.
Delta is also celebrating the 15th anniversary of its Breast Cancer One (BC1) Charter, which brings together employees whose lives have been affected by breast cancer. The 2026 charter will operate from October 7 to 9, traveling from Atlanta to Las Vegas. The program includes a welcome celebration, discussions with BCRF researchers, and a private F1 Arcade experience. Breast cancer survivor Bridget Bahl will participate in the program, sharing her experience and promoting awareness, early detection, and research.
In addition to its research funding and charter program, Delta is taking its breast cancer awareness campaign to its customers during October. The airline will offer special pink-themed touches and opportunities for customers to contribute to BCRF. Customers can make direct donations to BCRF through Delta's dedicated campaign platform or donate miles through the airline's SkyWish program. Delta's objective remains focused on supporting research and helping create a future where fewer people are affected by breast cancer.
Key points
- Delta Air Lines commits over $36m to global breast cancer research, marking 21 years of partnership with Breast Cancer Research Foundation.
- The new fund established by Delta will help create new opportunities for researchers worldwide to secure funding and encourage international collaboration.
- Delta's breast cancer awareness campaign will be promoted to customers during October, with special pink-themed touches and opportunities to contribute to BCRF.
